Real‑world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib
Patients were mostly male (62.8%) with primary myelofibrosis (76.5%) and initiated FEDR at a mean age of 67.7 years.
Patients were mostly male (62.8%) with primary myelofibrosis (76.5%) and initiated FEDR at a mean age of 67.7 years.
This statement confirms the demographic and disease profile of the real‑world cohort receiving fedratinib, illustrating that the drug is being used in typical patients with primary myelofibrosis at a standard dose and age range.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Management of Acute Myeloid Leukemia: A Review
- Treatment of Acute Myeloid Leukaemia
- Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates
- Research blog: Accelerating progress in AML
- Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012